GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Debt-to-EBITDA

Zenith Capital (Zenith Capital) Debt-to-EBITDA : 0.00 (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zenith Capital's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Zenith Capital's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Zenith Capital's annualized EBITDA for the quarter that ended in . 20 was $0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Zenith Capital's Debt-to-EBITDA or its related term are showing as below:

ZHCLF's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.31
* Ranked among companies with meaningful Debt-to-EBITDA only.

Zenith Capital Debt-to-EBITDA Historical Data

The historical data trend for Zenith Capital's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Debt-to-EBITDA Chart

Zenith Capital Annual Data
Trend
Debt-to-EBITDA

Zenith Capital Quarterly Data
Debt-to-EBITDA

Competitive Comparison of Zenith Capital's Debt-to-EBITDA

For the Biotechnology subindustry, Zenith Capital's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenith Capital's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Debt-to-EBITDA falls into.



Zenith Capital Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zenith Capital's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Zenith Capital's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (. 20) EBITDA data.


Zenith Capital  (OTCPK:ZHCLF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Zenith Capital Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenith Capital (Zenith Capital) Business Description

Traded in Other Exchanges
N/A
Address
300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1
Website
Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines